Adverse incidents: in vitro diagnostic (IVD) blood glucose meters

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides this guidance for manufacturers regarding the reporting of adverse incidents involving In Vitro Diagnostic (IVD) blood glucose monitors. This document functions as part of the broader vigilance system and should be applied alongside general post-market surveillance guidelines. Since this is a regulatory guidance document rather than an enforcement action, no specific company or inspection dates are cited; however, it applies to all manufacturers operating within the UK regulatory framework. The guidance addresses critical issues such as device malfunctions, inaccurate readings, and labeling errors that could lead to incorrect medical decisions, such as improper insulin dosing. Under the established regulatory framework, manufacturers are required to implement systematic procedures to identify and investigate incidents. Key required actions include reporting any device failure or deterioration in performance to the MHRA if it could cause death or serious health issues. Manufacturers must submit timely reports and conduct thorough root cause analyses to ensure patient safety and maintain compliance with legal obligations for post-market monitoring.